Kadmon — Investor Presentation (June 2018)
25 slides from Kadmon's investor presentation, Jun 11, 2018
Slide 1: Kadmon Holdings, Inc. Corporate Presentation June 2018
1 Kadmon Holdings, Inc. Corporate Presentation June 2018
Slide 2: Disclaimers
2 2 Disclaimers This presentation contains “forward - looking” statements that are based on the beliefs and assumptions and on information currently available to management of Kadmon Holdings, Inc . (the “Company”) . All statements other than statements of historical fact contained in this presentat
Slide 3: Innovative Pipeline for Significant Unmet Medical Needs
3 3 Innovative Pipeline for Significant Unmet Medical Needs Clinical - Stage Compounds Indication Preclin. Phase 1 Phase 2 Status Inflammatory and Fibrotic Diseases KD025 (ROCK2 inhibitor) Chronic Graft - Versus - Host Disease (cGVHD) Phase 2 ongoing; Pivotal trial planned Q3 2018 Scleroderma (Syste
Slide 4: ROCK Inhibitor Platform: Inflammatory and Fibrotic Diseases
4 ROCK Inhibitor Platform Inflammatory and Fibrotic Diseases
Slide 5: The Role of the ROCK Signaling Pathway
5 5 The Role of the ROCK Signaling Pathway ROCK Signaling Pathway Plays a Key Role in Multiple Tissue Types Rho - associated coiled - coil kinase (ROCK) is a serine/threonine kinase that mediates a wide range of functions, including cell movement, shape, differentiation and function 1 Two isofor
Slide 6: ROCK2 Rebalances Immune Response to Treat Immune Dysfunction
6 6 ROCK2 Rebalances Immune Response to Treat Immune Dysfunction ROCK2 Inhibition Downregulates STAT3 and Upregulates STAT5 Pathways STAT3 (Th17) STAT5 (Treg) Inflammation Resolution Inflammation Resolution STAT3 (Th17) STAT5 (Treg) ROCK2 Activation ROCK2 Inhibition ROR g t IRF4 ROCK2 inhibition d
Slide 7: ROCK is the Common Pathway of Initiating Factors in Fibrosis
7 7 ROCK is the Common Pathway of Initiating Factors in Fibrosis ROCK Regulates Multiple Pro - Fibrotic Processes, Including Myofibroblast Activation ROCK is downstream of major pro - fibrotic mediators, including: – Transforming growth factor beta (TGF - β ) – Connective tissue growth factor (CTG
Slide 8: KD025: A ROCK2-Selective Inhibitor
8 8 KD025: A ROCK2 - Selective Inhibitor KD025 is Kadmon’s Lead ROCK2 Inhibitor In Phase 2 Development KD025 is a selective oral ROCK2 inhibitor in Phase 2 clinical development for inflammatory and fibrotic diseases – Demonstrated a favorable tolerability profile and clinical activity in 8 complet
Slide 9: KD025: Chronic Graft-Versus-Host-Disease (cGVHD)
9 9 KD025: Chronic Graft - Versus - Host - Disease (cGVHD) cGVHD: Complication Following HSCT Life - threatening condition following stem cell transplant from blood or bone marrow (hematopoietic stem cell transplantation (HSCT)) Transplanted immune cells (graft) attack healthy cells (host), lead
Slide 10: cGVHD Treatment Landscape
10 10 cGVHD Treatment Landscape Currently Available cGVHD Therapies Steroids are first - line treatment for cGVHD Ibrutinib received FDA approval in August 2017 for adults with cGVHD after failure of one or more lines of systemic therapy 1 Enrollment criteria required 25% body surface area ery
Slide 11: Ongoing Ph2 Trial of KD025 in cGVHD: Design and Key Endpoints
11 11 Ongoing Ph2 Trial of KD025 in cGVHD: Design and Key Endpoints Cohort 1: 200mg QD (n=16) Cohort 2: 200mg BID (n=16) Cohort 3: 400mg QD (n= 16 ) Enrollment per trial design; actual enrollment: Cohort 1 (n=17); Cohort 2 (n=16); Cohort 3 ( ongoing ) 1 2014 National Institutes of Health (NIH) Conse
Slide 12: KD025 Associated With Robust Overall Responses
12 12 KD025 Associated With Robust Overall Responses Approximately Two - Thirds of Patients Achieved a Clinical Response with KD025 KD025 was well tolerated: – No treatment - related SAEs – No apparent increased risk of infection ORRs of 65% and 69% in Cohorts 1 and 2, respectively – Observed CR
Slide 13: KD025 in cGVHD: Regulatory Pathway
13 13 KD025 in cGVHD: Regulatory Pathway Planned Regulatory Pathway for KD025 in cGVHD FDA Type C meeting with Kadmon on March 22, 2018 to receive guidance on development pathway Based on FDA guidance, Kadmon plans to initiate an open - label pivotal Phase 2 trial in cGVHD – Two dose levels: KD0
Slide 14: KD025-213: Planned Pivotal Trial of KD025 in cGVHD
14 14 KD025 - 213: Planned Pivotal Trial of KD025 in cGVHD KD025 200 mg BID (n=63) KD025 200 mg QD (n=63) Treat to progression Primary Endpoint: • ORR, per 2014 NIH criteria Key Secondary Endpoints: • Durability of response • Response by organ system • Lee Symptom Score • Changes in corticosteroid a
Slide 15: KD025-209: Planned Phase 2 Clinical Trial in Scleroderma
15 15 KD025 - 209: Planned Phase 2 Clinical Trial in Scleroderma Scleroderma (Systemic Sclerosis) Background Scleroderma (also known as systemic sclerosis) is a chronic multi - system disease characterized by skin thickening and internal organ fibrosis – Approximately 75,000 to 100,000 people in t
Slide 16: KD025: Idiopathic Pulmonary Fibrosis (IPF)
16 16 KD025: Idiopathic Pulmonary Fibrosis (IPF) IPF: Major Unmet Medical Need IPF is a progressive fibrotic disease of the lungs – Believed to be caused by repetitive environmental injury to lining of the lungs and resulting abnormal wound - healing responses – Prolonged activation of wound - hea
Slide 17: KD025 in IPF: Demonstrated Clinical Activity
17 17 KD025 in IPF: Demonstrated Clinical Activity 1 KD025 - 207: Open - label, 24 - week trial of 39 patients randomized 2:1 to receive KD025 400 mg QD or Best Supportive Care (BSC) KD025 slowed the decline in lung function in IPF patients at 24 weeks 2 : – Absolute change in FVC of - 50 mL in
Slide 18: KD025 Clinical Activity Maintained Through Week 48
18 18 KD025 Clinical Activity Maintained Through Week 48 1 Range of Δ FVC in treatment arms of Phase 3 studies of approved IPF therapies nintedanib and pirfenidone 2,3 Range of Δ FVC in placebo arms of Phase 3 studies of approved IPF therapies 2,3 1 Not a head - to - head comparison 2 Supplement t
Slide 19: Wilson's Disease Background and KD034
19 19 Wilson’s Disease Background Wilson’s Disease is a genetic disorder characterized by an inability to excrete copper – Leads to severe hepatic, neurologic, psychiatric and/or ophthalmic abnormalities – 10,000 living with Wilson’s Disease in the United States – Currently available treatments re
Slide 20: Preclinical Research
20 Preclinical Research
Slide 21: Kadmon Drug Discovery Platform
21 21 Kadmon Drug Discovery Platform Robust Drug Discovery Platform 24 - person team developing small molecules and biologics Lead program: Third - generation ROCK inhibitors optimized for clinical development Platform Target Potential Indication(s) Small Molecules Rho associated coiled - coil c
Slide 22: KD045, Lead ROCK Inhibitor Candidate
22 22 KD045, Lead ROCK Inhibitor Candidate Kadmon ROCK Inhibitor Program Overview hinge Activation loop G - loop KD045 Discovery goal: Identify and develop proprietary third - generation ROCK inhibitors optimized for clinical development – Develop candidates with improved potency, specificity, “dr
Slide 23: KD033: Lead IL-Fusion Platform Candidate
23 23 KD033: Lead IL - 15 Fusion Platform Candidate KD033 (anti - PD - L1/IL - 15 Fusion Protein ): IND Anticipated 2H 2019 Anti - PD - L1 alone, 10 mg/kg Anti - PD - L1/IL - 15 (KD033 surrogate ), 3.3 mg/kg Vehicle n=12 Dosing, once a week Day 54 Day 77 Day 124 % Survival Days after tumor inoculati
Slide 24: Company Summary
24 24 Company Summary Leader in R&D of ROCK Inhibitors KD025: Selective ROCK2 inhibitor in Phase 2 clinical development: – Open - label, dose - finding trial in cGVHD – Randomized, open - label trial in IPF Generated a portfolio of preclinical ROCK inhibitors for inflammatory and fibrotic diseas
Slide 25: Financial Profile
25 25 Financial Profile KDMN Financial Summary Cash and cash equivalents of $49.2 million as of March 31, 2018 78,794,746 common shares outstanding as of May 4, 2018 Trades on the NYSE under the ticker symbol “KDMN”